Inhibrx Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| INBX | IVA | SNDX | BHVN | OBX | NRIX | |
|---|---|---|---|---|---|---|
| Market cap | 1.33B | 737.01M | 1.48B | 1.78B | 790.08M | 2.30B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -10.3 | -4.2 | -19.4 | -6.3 | -6.0 | -20.8 |
| Price/book | -25.1 | -18.2 | 97.9 | 145.8 | -1.0 | 5.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +176.35% | −31.45% | +11.78% | −29.11% | −25.71% | +129.94% |
| Today | −4.72% | −1.27% | −2.59% | −2.24% | −1.62% | −0.85% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All INBX news ›Inhibrx Biosciences, Inc. (NASDAQ:INBX) Stock Has Consensus Price Target of $197.50
Posted by Danessa Lincoln on Oct 6th, 2026 Read Our Latest Analysis on INBX Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.